견적문의

TORRANCE, CALIF.--( / )--VIEW E-MEDIA KIT () - Emmaus Life Sciences, Inc. (Emmaus) announced today that the New England Journal of Medicine (NEJM) has published the results of its 48-week phase 3 clinical trial of Endari™ (L-glutamine oral powder) which supported the FDA approval in July 2017 to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older.

The article reports results that showed significantly fewer sickle cell crises in those receiving Endari compared to placebo by 25 percent; p=0.005 (median 3 vs. median 4) and significantly fewer hospitalizations by 33 percent; p=0.005 (median 2 vs. median 3). Additional findings showed lower cumulative days in hospital of 41 percent; p=0.02 (median 6.5 days vs. median 11 days) and a lower incidence of acute chest syndrome (ACS) by more than 60 percent; p=0.003 (13 of 152 patients [8.6%] had at least 1 ACS compared with 18 of 78 in the placebo group [23.1%]). The most common adverse reactions, occurring in greater than 10 percent, of the clinical study were constipation, nausea, headache, abdominal pain, cough, pain in extremity, back pain, and chest pain.

“Endari is the first approved treatment for sickle cell disease in pediatric patients 5 years of age and older and the first in nearly 20 years for adults. Our hope in sharing the results of this data from the New England Journal of Medicine, a publication with worldwide reach and significance, is to aid in increasing the awareness of sickle cell disease, a lifelong hereditary blood disorder which commonly affects those of African descent, as well as those from Central and South America and people of Middle Eastern, Asian, Indian and Mediterranean descent,” said co-author Yutaka Niihara, MD, CEO and founder of Emmaus.

“Sickle cell disease affects thousands of people in the United States,” said Beverley Francis-Gibson, President and CEO of The Sickle Cell Disease Association of America, Inc. “While there is no universal cure for this life-threatening disease, patient awareness and education on treatment options remain important factors for the sickle cell community.”

Additional Information About the Phase 3 Clinical Study

The randomized, double-blind, placebo-controlled, multicenter Phase 3 trial evaluated the efficacy and safety of Endari (0.3 gram per kilogram of body weight per dose) administered twice daily by mouth, as compared with placebo. The study included patients at least 5 years of age with sickle cell anemia or sickle β0-thalassemia, with a history of two or more pain crises during the previous year. Patients who were receiving hydroxyurea at a dose that had been stable for at least 3 months before screening and who continued such therapy during the 48-week treatment period were eligible. A total of 230 patients (age range, 5 to 58 years; 53.9% female) were randomly assigned, in a 2:1 ratio, to receive L-glutamine (152 patients) or placebo (78 patients).

About Sickle Cell Disease

Sickle cell disease is an inherited blood disorder characterized by the production of an altered form of hemoglobin which polymerizes and becomes fibrous, causing red blood cells to become rigid and change form so they appear sickle shaped instead of soft and rounded. Patients with sickle cell disease suffer from debilitating episodes of sickle cell crises, which occur when the rigid, adhesive and inflexible red blood cells occlude blood vessels. Sickle cell crises cause excruciating pain as a result of insufficient oxygen being delivered to tissue, referred to as tissue ischemia, and inflammation. These events may lead to a variety of other adverse outcomes such as acute chest syndrome that requires hospitalization. Sickle cell disease is an orphan disease, affecting approximately 100,000 patients in the U.S. and millions worldwide, with significant unmet medical needs.

About Endari

Endari (L-glutamine oral powder) is a prescription oral treatment approved by the U.S. Food and Drug Administration (FDA) to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older. Endari was approved in July 2017 and was the first treatment in nearly 20 years shown to reduce the acute complications of sickle cell disease in adults when used as directed. Endari is also the first treatment approved to reduce the acute complications of sickle cell disease in children five years and older when used as directed. Endari has received Orphan Drug designation in the U.S., and Orphan Medicinal Product designation in the EU.

Important Safety Information

The most common adverse reactions (incidence >10 percent) in clinical studies were constipation, nausea, headache, abdominal pain, cough, pain in extremities, back pain and chest pain.

Adverse reactions leading to treatment discontinuation included one case each of hypersplenism, abdominal pain, dyspepsia, burning sensation and hot flash.

The safety and efficacy of Endari in pediatric patients with sickle cell disease younger than five years of age has not been established.

For more information, please see full Prescribing Information of Endari at:

About Emmaus Life Sciences, Inc.

Emmaus Life Sciences, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of innovative treatments and therapies primarily for rare and orphan disease. Its lead product, Endari, demonstrated positive clinical results in the completed Phase 3 clinical trial for sickle cell anemia and sickle ß0-thalassemia and has received FDA approval. Visit:

Forward-Looking Statements

This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, regarding the research, development and potential commercialization of pharmaceutical products. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. Additional risks and uncertainties are described in reports filed by Emmaus Life Sciences, Inc., with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Emmaus is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.

Article Reference

Niihara, Y, et al. A Phase 3 Trial of L-Glutamine in Sickle Cell Disease. NEJM to be published 19 July 2018

View source version on businesswire.com:Korea Newswire distributes your news across every media channels through the industry’s largest press release distribution network

BONN, 성산면맞고 로또분석사이트 GERMANY--( / )--Mavenir, the Network Software Provider building 올스티비TV 남자들이좋아하는여자비키니 the future of networks with cloud-native solutions that run on any cloud, today announces the deployment 케이걸스 BONN,its cloud-based Remote Packet Gateway to Deutsche Telekom IoT GmbH in North America, 올스티비TV 로또분석번호 with the initial use case focused 올스티비TV 로또리치당첨 on delivering IoT connectivity to several industry-leading car manufacturers.

Consumer behaviour within the automotive industry is shifting, with customers looking more for sustainable mobility and fewer people wanting 올스티비TV 비키니라인제모집에서 to own a car as 성산면맞고 셀프비키니라인제모 a status symbol. Electric Vehicles (EVs) 올스티비TV 연예인비키니제모 and car sharing are currently key trends, and the advent of connected cars will ultimately lead to autonomous driving - 오르가즘 Consumerpressure on automakers and suppliers to make their supply chains resilient. All of these contributing factors are driving the industry need for automotive IoT.

Deutsche Telekom IoT GmbH is deploying Mavenir’s Remote Packet Gateway 4G and 5G 올스티비TV 로도복권 non-standalone (NSA) solutions to enable localised data breakout, allowing traffic to be routed 올스티비TV through two data centres in California and Virginia - supporting IoT deployment applications across the continent. 올스티비TV 최고노출

The Remote Packet Gateway uses the Converged Packet Core Session Management and User Plane Functionality, which function as 미유키아리스 Thecomponents replicating the Packet Gateway's control and 올스티비TV 여자들이좋아하는남자행동1위 user planes. This separation of control and user plane enables reduced latency for user data, reduced data transfers via transatlantic transmissions, and supports advanced connectivity services with different charging options in vehicles, including internet radios, in-car Wi-Fi, telemetry data, remote map and Short Wave upgrades. Additionally, Mavenir’s solution empowers Deutsche Telekom IoT GmbH to provide capabilities and connectivity services internationally to multinational companies, without geographical or technological constraints.

Ashok Khuntia, Mavenir President Core Networks, said, “Mavenir’s solution deployed with 올스티비TV 각선미여대생 Deutsche Telekom IoT GmbH will create the foundation 올스티비TV 전혜빈장우혁 for the future of connected vehicles. The applications enabled by this partnership will 올스티비TV allow car manufacturers to benefit from advanced connectivity and an improved customer offering serving the needs 성산면맞고 of today with a vision for the future.”

About 올스티비TV 복권당첨금수령 Deutsche 성산면맞고 아이보스 Telekom: 올스티비TV

For 올스티비TV 복권당첨번호조회 more 올스티비TV 블로그도우미 amouranth For올스티비TV 복권당첨자

About 성산면맞고 블로거세상 amouranth About올스티비TV 분당수학과외

Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision 올스티비TV 블로그광고비용 of a single, software-based automated network that runs on any cloud. As the industry’s only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, 올스티비TV accelerating software network transformation for 250+ Communications Service 성산면맞고 쉽게돈버는방법 Providers and Enterprises in over 120 countries, which serve more than 50% of the world’s subscribers.

View amouranth Viewversion on businesswire.com:Korea Newswire distributes your news across every media channels through the industry’s largest 올스티비TV 그린닥터성북점 press release distribution network